[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"richter-transformation-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:richter-transformation-lymphoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100649540","phase-1-a-phase-12-study-of-ub-vv400-with-rapamycin-in-relapsedrefractory-b-cell-malignancies-100649540",false,"NCT07735533","A Phase 1\u002F2 Study of UB-VV400 With Rapamycin in Relapsed\u002FRefractory B-cell Malignancies","A Phase 1\u002F2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory large B-cell lymphoma (LBCL)\n4. Measurable disease according to Lugano 2014 criteria\n5. Confirmed CD22 expression\n6. No serious concomitant diseases or active\u002Funcontrolled infections\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n8. Adequate organ function\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding\n2. Current isolated central nervous system (CNS) involvement\n3. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor \\[TCR\\] fusion constructs, TCR T cells, and CAR T cells)\n4. History of or active human immunodeficiency virus (HIV)\n5. Active or chronic hepatitis B, or active hepatitis C\n6. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n7. Ongoing CNS disease that would preclude neurologic assessment\n8. Uncontrolled angina or other acute heart disease\n9. Currently receiving treatment in another interventional clinical trial.","ALL","18 Years",{"count":19,"type":20},274,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study is a Phase 1\u002F2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed\u002Frefractory B-cell malignancies, including large B-cell lymphoma (LBCL).",[27,28,29,30,31,32,33],"Lymphoma, B Cell","Lymphoma Non-Hodgkin","High Grade B Cell Lymphoma","Richter Transformation Lymphoma","Grade 3b Follicular Lymphoma","Primary Mediastinal B Cell Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)",[35,36,37],"CAR T","chimeric antigen receptor","CD22","NOT_YET_RECRUITING","2026-08-13",{"date":41,"type":42},"2026-08-17","ACTUAL",{"date":44,"type":20},"2026-08",{"date":46,"type":20},"2031-08",{"name":48,"class":49},"Umoja Biopharma","INDUSTRY"]